Combinaison de Dapagliflozin et de Saxagliptin pour une amélioration du métabolisme du glucose dans le diabète de type 2

This study focuses on improving treatment for type 2 diabetes, specifically for patients whose condition is not well-managed with metformin. The study involves two medications: Dapagliflozin (Forxiga) and Saxagliptin. Dapagliflozin works by promoting glucose excretion in the urine, lowering blood sugar levels. Saxagliptin, on the other hand, is a DPP4 inhibitor that helps increase insulin production and decrease glucagon concentrations, leading to lower blood sugar levels. The goal of this research is to explore how these two drugs, when used together with metformin, can improve glucose metabolism in type 2 diabetes patients. During the study, participants will be randomly assigned to receive either a combination of Dapagliflozin and Saxagliptin, or one of these drugs alone, in addition to their current metformin treatment. The primary outcome measured is the effect of these treatments on pancreatic hormone secretion and endogenous glucose production. This will be evaluated by comparing the results of the combined therapy with those of the individual drugs. The study aims to understand if the combination of Dapagliflozin and Saxagliptin can offer improved blood sugar control for type 2 diabetes patients who are not adequately managed with metformin alone.